Repligen Corporation (RGEN) shares rose 4.3% to $189.50 as of October 5, 2026, a moderate gain from the prior close of $181.70. BestStocks flagged the session as a major change for RGEN. The move is tied to price move up. Below, we break down what changed for RGEN, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
RGEN climbed 4.3% to $189.50
Repligen Corporation (RGEN) moved +6.01% from $178.75 to $189.50 on 2026-10-05. We checked news, earnings announcements, analyst updates, filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average. Repligen's Q3 earnings on 2026-10-27 will be the next concrete catalyst to assess whether results align with or diverge from the $0.46 consensus estimate.
This summary describes the catalyst and move as first detected on Oct 5, 2026, 4:39 PM EDT; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
Material / EarningsLow confidence
Rel. volume
1.5×
Normal
Vs peers
—
No comparable peers
Market cap
$10.7B
NASDAQ Global Select
Analyst target
$162
-14.3% vs price
Price chart
Sep 4 – Oct 5
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Repligen Corporation investors
For Repligen Corporation investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Material positive event; Positive 4.3% session move. Weighing against that: Repligen Corporation (RGEN) moved -5.84% from $145.49 to $136.99 on 2026-07-21; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $162.43, implying -14.3% downside from $189.50. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality low (59/100). With earnings roughly 29 days out, the next report is the most likely near-term test of the move.
RGEN price reaction
RGEN last traded at $189.50, up $7.80 (+4.29%) from the previous close of $181.70. The session traded on 1.5× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $164.68 and $194.57, and it currently sits about 83% of the way up that band.
Bullish and bearish analyst opinions on Repligen Corporation (RGEN)
The consensus analyst price target on Repligen Corporation (RGEN) is $162.43, 14.3% below the recent $189.50. Over the past 90 days analysts logged 1 upgrade, 3 maintains, and 0 downgrades. Here is how the bullish and bearish cases on RGEN line up.
▲ The bullish case
+The Street's most bullish target is $225.00 (+18.7%).
+1 analyst upgrade in the past 90 days, most recently Benchmark to Buy (2026-07-07).
+Material positive event.
+Positive 4.3% session move.
+Positive price momentum.
▼ The bearish case
−The consensus analyst price target of $162.43 sits 14.3% below the recent $189.50, so the average target sees limited room to run.
−The most bearish analyst target is $142.00 (-25.1%).
−Repligen Corporation (RGEN) moved -5.84% from $145.49 to $136.99 on 2026-07-21.
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 5, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Repligen beat Q2 earnings estimates on October 1, 2026, yet the stock fell 7.10% to $178.57 from $192.23 intraday (per Yahoo Finance). Volume of 1.47x normal suggests active selling despite the positive earnings surprise, indicating a sell-the-news or guidance-driven reaction.
Material / Earnings2026-09-28+2.3%
RGEN moved +3.65% from its $187.25 open to a $194.09 close on 2026-09-28.
Repligen Corporation moved +2.15% intraday from $184.53 to $188.50. Repligen Corporation (RGEN) stock is up today because it is continuing a multi-week momentum surge that pushed the stock to a new 52-week high of $190.01.While there is no new company-specific catalyst filed today, the upward movement is driven by a broader wave of investor optimism, recent Wall Street price target upgrades (including Argus raising its target to $196.00), and continued positive sentiment from its raised 2026 financial guidance and pending BioLife Solutions acquisition. ## Repligen Corp (RGEN) $188.75 2.29% today As of Sep 24, 1:31 PM EDT • Disclaimer 10:00 AM 11:00 AM 12:00 PM 1:00 PM 186 188 Prev close $184.53 Sep 24, 2026 9:30 AM - 1:31 PM 1D 5D 1M 6M YTD 1Y 5Y Max| Open 184.10 | Mkt cap $10.65B USD | 52-wk high 190.01 | | High 190.01 | P/E ratio 257.28 | 52-wk low 100.99 | | Low 183.75 | Div yield- | ### Core Factors Driving the Recent Gains: - Analyst Upgrades: Research firms have continuously revised their outlooks upward, with recent reports boosting price targets up to $196.00 and UBS initiating coverage with a Buy rating and a $225 target earlier this month. - Sector Rotation & ETF Inflows: Life sciences tools and bioprocessing stocks are experiencing a str
Material / Earnings2026-09-22+3.3%
RGEN moved +3.31% from its $180.72 open to a $186.70 close on 2026-09-22.
Filings2026-09-15+4.0%
Repligen Corporation (RGEN) filed a new 8-K on September 15, 2026. The filing details were not disclosed in available sources.
Material / Earnings2026-09-15+4.0%
Repligen Corporation (RGEN) moved +3.84% from $168.27 to $174.73 on 2026-09-15. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average.
Material / Earnings2026-09-03-1.9%
Repligen Corporation (RGEN) moved -3.37% from $175.53 to $169.61 on 2026-09-03. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was 1.4x the 5-day average, modestly elevated.
In-depth RGEN event analyses
Permanent, dated analyses of RGEN's most significant sessions.
RGEN rose 4.3% to $189.50. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did RGEN stock rise?
RGEN gained 4.29% ($7.80) versus the prior close of $181.70, last trading at $189.50 on 1.5× average volume.
When is Repligen Corporation's next earnings date?
RGEN's next earnings report is estimated for 2026-11-03 — about 29 days away.
What is the analyst price target for RGEN?
The consensus analyst price target for RGEN is $162.43, about 14.3% below the current $189.50. Over the past 90 days, analysts recorded 1 upgrade, 3 maintains, and 0 downgrades.
How BestStocks tracks RGEN
This page is generated automatically by BestStocks' change-detection system after price move up was detected and verified against independent data sources. It draws on 20 tracked change events for RGEN, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 5, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
